By: Elai Katz, Lisa P. Rumin & Betty Zhang (McDermott Will & Emery Antitrust Alert)
Pharmaceutical patent holders take note: Over the past year, antitrust enforcers have intensified their scrutiny of Orange Book listings, viewing them as potentially anticompetitive. The Federal Trade Commission has stated that improperly listing patents in the Orange Book can constitute an unfair method of competition, among other legal violations.
In this article, Elai Katz, Lisa Rumin, and Betty Zhang examine this increased focus on Orange Book listings and outline the risks brand-name drug manufacturers should be mindful of regarding their listing practices. Moving forward, these manufacturers should adopt a proactive approach by thoroughly documenting their evaluation process and the rationale behind listing patents in the Orange Book to ensure compliance with statutory requirements…
Featured News
Judge Dismisses Antitrust Lawsuit Against Ivy League Over Athletic Scholarships
Oct 11, 2024 by
CPI
FTC and DOJ Revamp Merger Guidelines to Identify Illegal Transactions More Efficiently
Oct 11, 2024 by
CPI
US Consumer Watchdog Eyes Expansion of ‘Junk Fee’ Crackdown Ahead of 2024 Election
Oct 10, 2024 by
CPI
Brazil Proposes Reform to Competition Law Targeting Big Tech
Oct 10, 2024 by
CPI
Meta Enhances User Data Control, Resolving German Antitrust Dispute
Oct 10, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh